Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD

43.99

+1.23 (2.88%)

At close: Jul 26, 2024, 4:00 PM

44.87

+0.88 (2.00%)

After-hours: Jul 26, 2024, 4:57 PM EDT

Janux Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	7.29	8.08	8.61	3.64	-	-
Revenue Growth (YoY)	-19.67%	-6.14%	136.79%	-	-	-
Cost of Revenue	53.13	54.92	53.44	26.24	3.04	-
Gross Profit	-45.84	-46.84	-44.83	-22.6	-3.04	-
Selling, General & Admin	27.02	26.14	22.26	10.33	1.8	0.77
Research & Development	-	-	-	-	-	3
Operating Expenses	27.02	26.14	22.26	10.33	1.8	3.77
Operating Income	-72.86	-72.98	-67.09	-32.93	-4.84	-3.77
Interest Expense	-	-	-	-	-0.21	-0.23
Interest & Investment Income	17.27	14.69	4.03	0.26	-	-
EBT Excluding Unusual Items	-55.59	-58.29	-63.06	-32.67	-5.05	-4
Other Unusual Items	-	-	-	-	-1.74	-
Pretax Income	-55.59	-58.29	-63.06	-32.67	-6.78	-4
Net Income	-55.59	-58.29	-63.06	-32.67	-6.78	-4
Net Income to Common	-55.59	-58.29	-63.06	-32.67	-6.78	-4
Shares Outstanding (Basic)	46	44	41	24	1	1
Shares Outstanding (Diluted)	46	44	41	24	1	1
Shares Change (YoY)	10.24%	6.14%	76.24%	2471.20%	36.71%	-
EPS (Basic)	-1.21	-1.32	-1.52	-1.39	-7.41	-5.98
EPS (Diluted)	-1.21	-1.32	-1.52	-1.39	-7.41	-5.98
Free Cash Flow	-53.26	-52.43	-49.37	-18.46	-4.37	-3.83
Free Cash Flow Per Share	-1.16	-1.19	-1.19	-0.78	-4.77	-5.72
Operating Margin	-999.85%	-902.87%	-779.04%	-905.39%	-	-
Free Cash Flow Margin	-730.93%	-648.58%	-573.24%	-507.51%	-	-
EBITDA	-70.83	-71.02	-66.25	-32.82	-4.83	-3.77
D&A For EBITDA	2.03	1.96	0.84	0.11	0.01	0.01
EBIT	-72.86	-72.98	-67.09	-32.93	-4.84	-3.77

Source: S&P Capital IQ. Standard template.